Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Transfusion ; 61(1): 202-211, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33166431

RESUMEN

BACKGROUND: Therapeutic phlebotomy is the standard treatment of hereditary hemochromatosis (HH), the most common genetic disease in people of Northern European descent. Red cell concentrates from HH donors have been reported safe for transfusion, but little data is available on the storage properties of platelet concentrates from HH donors. STUDY DESIGN AND METHODS: Whole blood was collected from 10 healthy individuals and 10 newly diagnosed HH patients with elevated serum ferritin. Platelet-rich plasma (PRP) was prepared and split into four 20-mL units. Platelet quality tests were performed on days 0, 1, 3, 5, and 7 of storage, including platelet aggregation (ADP, arachidonic acid, collagen, and epinephrine agonists), blood gas analysis, flow cytometry (CD41, CD42b, and CD62P expression), and ELISA (sCD40L and sCD62p in supernatant). RESULTS: Mean serum ferritin levels were higher in HH patients than in controls (847.5 vs 45.8 ng/mL, P < .001). Overall, no difference in quality test results was observed between the two study groups over 7-day storage (P > .05), including blood gas analysis, platelet aggregation, and expression of surface (CD62p and CD42b) and secreted (sCD62P and sCD40L) activation markers. Expected alterations in metabolic (CO2 and glucose decrease, O2 and lactate increase, P < .001) and platelet activation markers (CD42b decrease, CD62P increase, P < .05) over time were observed in both groups. CONCLUSION: Although these findings indicate that platelets of individuals with HH are comparable to platelets from healthy donors, more extensive studies are needed before definite conclusions can be drawn.


Asunto(s)
Donantes de Sangre/estadística & datos numéricos , Plaquetas/citología , Conservación de la Sangre/métodos , Hemocromatosis/diagnóstico , Adulto , Análisis de los Gases de la Sangre/métodos , Plaquetas/fisiología , Conservación de la Sangre/estadística & datos numéricos , Femenino , Ferritinas/sangre , Citometría de Flujo/métodos , Voluntarios Sanos , Hemocromatosis/sangre , Hemocromatosis/etnología , Hemocromatosis/terapia , Humanos , Masculino , Persona de Mediana Edad , Selectina-P/metabolismo , Flebotomía/métodos , Activación Plaquetaria/fisiología , Agregación Plaquetaria/fisiología , Pruebas de Función Plaquetaria/métodos , Complejo GPIb-IX de Glicoproteína Plaquetaria/metabolismo , Plasma Rico en Plaquetas/metabolismo
2.
Transfusion ; 60(1): 175-183, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31850521

RESUMEN

BACKGROUND: Rhesus D (RhD) incompatibility is still the most important cause of hemolytic disease of the fetus and newborn (HDFN) worldwide. The aim of this study was to investigate the incidence, causes, and consequences of anti-D alloimmunizations in pregnancy in Iceland, prior to implementation of targeted routine antenatal anti-D prophylaxis (RAADP) in 2018. STUDY DESIGN AND METHODS: This was a nation-wide cohort study of 130 pregnancies affected by RhD alloimmunization in Iceland in the period from 1996 through 2015. Data were collected from transfusion medicine databases, medical records, and the Icelandic Medical Birth Register. RESULTS: Of 130 RhD alloimmunizations, 80 cases (61.5%) represented new RhD immunization in the current pregnancy. Sensitization was discovered in the third trimester in 41 (51.3%) and occurred in the first pregnancy in 14 cases (17.5%). The most likely causative immunization event was the index pregnancy for 45 (56.25%), a previous pregnancy/birth for 26 (32.5%), abortion for 3 (3.75%), and unknown for 6 women (7.5%). Higher anti-D titers were associated with shorter gestational length, cesarean sections, positive direct antiglobulin test (DAT), and severe HDFN. Intrauterine transfusion (IUT) was performed in five pregnancies (3.8%), and 35 of 132 (26.5%) live-born neonates received treatment for HDFN; 32 received phototherapy (24.2%), 13 exchange transfusion (9.8%), and seven simple blood transfusion (5.3%). CONCLUSION: In about half of cases, RhD alloimmunization was caused by the index pregnancy and discovered in the third trimester. Thus, the newly implemented RAADP protocol should be effective in reducing the incidence of RhD immunization in Iceland in the future.


Asunto(s)
Transfusión de Sangre Intrauterina , Nacimiento Vivo , Diagnóstico Prenatal , Isoinmunización Rh , Globulina Inmune rho(D)/sangre , Adulto , Anemia Hemolítica Autoinmune/sangre , Anemia Hemolítica Autoinmune/diagnóstico , Anemia Hemolítica Autoinmune/epidemiología , Anemia Hemolítica Autoinmune/prevención & control , Femenino , Humanos , Islandia , Recién Nacido , Embarazo , Estudios Retrospectivos , Isoinmunización Rh/sangre , Isoinmunización Rh/diagnóstico , Isoinmunización Rh/epidemiología , Isoinmunización Rh/prevención & control
3.
Nucleic Acids Res ; 46(20): e118, 2018 11 16.
Artículo en Inglés | MEDLINE | ID: mdl-30053193

RESUMEN

DNA damage assays have various limitations in types of lesions detected, sensitivity, specificity and samples that can be analyzed. The Northern Lights Assay (NLA) is based on 2D Strandness-Dependent Electrophoresis (2D-SDE), a technique that separates nucleic acids based on length, strandness, structure and conformation changes induced by damage. NLA is run on a microgel platform in 20-25 min. Each specimen is analyzed in pairs of non-digested DNA to detect single- and double-stranded breaks (DSBs) and Mbo I-digested DNA to detect other lesions. We used NLA to evaluate DNA in solution and isolated from human cells treated with various genotoxic agents. NLA detected and distinguished between single- and DSBs, interstrand and intrastrand DNA crosslinks, and denatured single-stranded DNA. NLA was sufficiently sensitive to detect biologically relevant amount of DNA damage. NLA is a versatile, sensitive and simple method for comprehensive and simultaneous analysis of multiple types of damage, both in purified DNA and in DNA isolated from cells and body fluids. NLA can be used to evaluate DNA quality in biosamples, monitor complex molecular procedures, assess genotoxicity, diagnose genome instability, facilitate cancer theranostics and in basic nucleic acids research.


Asunto(s)
Análisis Citogenético/métodos , Roturas del ADN de Doble Cadena , Daño del ADN , Electroforesis en Gel Bidimensional/métodos , Células Cultivadas , ADN de Cadena Simple/análisis , Células Endoteliales de la Vena Umbilical Humana , Humanos , Recién Nacido , Células MCF-7 , Masculino , Pruebas de Mutagenicidad , Ácidos Nucleicos/análisis , Sensibilidad y Especificidad
4.
Genes Chromosomes Cancer ; 50(2): 113-21, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21117067

RESUMEN

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) and numerous copy number aberrations (CNAs). Recently, gene expression profiling defined a proliferation gene expression signature in MCL where high scores predict shorter survival. We investigated 31 MCL cases using high-density single nucleotide polymorphism arrays and correlated CNA patterns with the proliferation signature and with clinical data. Many recurrent CNAs typical of MCL were detected, including losses at 1p (55%), 8p (29%), 9q (29%), 11q (55%), 13q (42%) and 17p (32%), and gains at 3q (39%), 8q (26%), 15q (23%) and 18q (23%). A novel deleted region at 20q (16%) contained only one candidate gene, ZFP64, a putative tumor suppressor. Unsupervised clustering identified subgroups with different patterns of CNAs, including a subset (19%) characterized by the presence of 11q loss in all cases and by the absence of 13q loss, and 3q and 7p gains. Losses at 1p, 8p, 13q and 17p were associated with increased genomic complexity. High proliferation signature scores correlated with increased number of large (>15 Mbp) CNAs (P = 0.03) as well as copy number gains at 7p (P = 0.02) and losses at 9q (P = 0.04). Furthermore, large/complex 13q losses were associated with improved survival (P < 0.05) as were losses/copy number neutral LOH at 19p13 (P = 0.01). In summary, this high-resolution genomic analysis identified novel aberrations and revealed that several CNAs correlated with genomic complexity, the proliferation status and survival.


Asunto(s)
Variaciones en el Número de Copia de ADN/genética , Regulación Neoplásica de la Expresión Génica , Pruebas Genéticas , Linfoma de Células del Manto/genética , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/genética , Deleción Cromosómica , Análisis por Conglomerados , Femenino , Perfilación de la Expresión Génica , Humanos , Estimación de Kaplan-Meier , Pérdida de Heterocigocidad , Masculino , Persona de Mediana Edad , Pronóstico , Eliminación de Secuencia
5.
Clin Chim Acta ; 389(1-2): 160-3, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18061576

RESUMEN

BACKGROUND: The purpose of this study was to investigate the degree of DeltaOD450 method variability and its effect on DeltaOD450 measurements between selected clinical laboratories in the U.S. METHOD: Four amniotic fluid specimens were sent to 7 clinical laboratories in the U.S. for DeltaOD450 analysis. In addition, scanning spectrophotometric data from 152 amniotic fluid samples were used to compare DeltaOD450 values calculated using both log and linear OD scales. RESULTS: We found that no 2 laboratories used exactly the same method and no laboratory used precisely the same method as originally described by Liley. Despite the varied methods, the DeltaOD450 measurements were remarkably similar. The exception was 1 sample that was subjected to chloroform extraction. The DeltaOD450 measurement on this sample was 82% lower than the mean. On average, DeltaOD450 results determined from a linear OD scale were 37% lower than those determined from a log scale. CONCLUSION: Although there is no standard method for performing the DeltaOD450, inter-laboratory variation of DeltaOD450 results is remarkably small. As our and other previous studies have reported, these data suggest that both chloroform extraction and use of a linear scale have the potential to result in lower DeltaOD450 results.


Asunto(s)
Líquido Amniótico/química , Bilirrubina/análisis , Análisis Espectral/métodos , Humanos
6.
Epigenetics ; 7(12): 1435-42, 2012 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-23154584

RESUMEN

Chronic lymphocytic leukemia (CLL) can be divided into prognostic subgroups based on the IGHV gene mutational status, and is further characterized by multiple subsets of cases with quasi-identical or stereotyped B cell receptors that also share clinical and biological features. We recently reported differential DNA methylation profiles in IGHV-mutated and IGHV-unmutated CLL subgroups. For the first time, we here explore the global methylation profiles of stereotyped subsets with different prognosis, by applying high-resolution methylation arrays on CLL samples from three major stereotyped subsets: the poor-prognostic subsets #1 (n = 15) and #2 (n = 9) and the favorable-prognostic subset #4 (n = 15). Overall, the three subsets exhibited significantly different methylation profiles, which only partially overlapped with those observed in our previous study according to IGHV gene mutational status. Specifically, gene ontology analysis of the differentially methylated genes revealed a clear enrichment of genes involved in immune response, such as B cell activation (e.g., CD80, CD86 and IL10), with higher methylation levels in subset #1 than subsets #2 and #4. Accordingly, higher expression of the co-stimulatory molecules CD80 and CD86 was demonstrated in subset #4 vs. subset #1, pointing to a key role for these molecules in the crosstalk of CLL subset #4 cells with the microenvironment. In summary, investigation of three prototypic, stereotyped CLL subsets revealed distinct DNA methylation profiles for each subset, which suggests subset-biased patterns of transcriptional control and highlights a key role for epigenetics during leukemogenesis.


Asunto(s)
Metilación de ADN , Regulación Leucémica de la Expresión Génica , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/inmunología , Antígeno B7-1/genética , Antígeno B7-1/metabolismo , Antígeno B7-2/genética , Antígeno B7-2/metabolismo , Femenino , Humanos , Cadenas Pesadas de Inmunoglobulina/genética , Activación de Linfocitos , Masculino , Pronóstico , Transcripción Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA